U,

According to Peter,when he was still with MannKind,the Type II trial does require titration.

"The other study will assess AFREZZA using the next generation inhaler in patients with Type 2 diabetes, who were inadequately controlled on Metformin with or without a second or third oral medication. Patients will be randomized to treatment with AFREZZA or placebo in the randomized fashion. Each arm is targeted to end with 123 patients. The study will have a 12-week titration period, followed by a 12-week observation period. And the goal of this studies is to evaluate the efficacy of AFREZZA compared to a placebo powder. "

http://seekingalpha.com/article/305499-mannkind-s-ceo-discusses-q3-2011-results-earnings-call-transcript?all=false&find=enrollment